The hypotheses to be tested in this study by analyzing plasma levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 in patients affected by AAA and treated by EVAR are as follows: First, plasma MMP-9 and MMP 2 levels will be elevated in AAA-affected patients compared to healthy control subjects. This evidence concerns the gene MMP9 and triple-A syndrome.